First Targeted Bladder Cancer Treatment Shows Promising Phase I Results
Posted:
In a potential win for targeted therapy in bladder cancer, Johnson & Johnson announced results from a Phase I study of erdafitinib (Erda-iDRS) in patients with the intermediate-risk non-muscle-invasive form of the disease.
The patients who watched the personalized AI avatar videos showed better understanding of their treatment plan, a greater ability to engage with health care decisions, and reduced stress compared to those who watched the standard educational video.
Read more here.
Once cancer has begun to spread within the body (metastasise) it generally becomes harder to treat and survival rates are lower. The new research focuses on patients with oligometastatic breast cancer, meaning a few small secondary tumors have broken away…
Attendees
Sponsors and Exhibitors
Contact us